Pembrolizumab Enhances Progression-Free Survival in HER2-Positive Gastro-Esophageal Cancer
Findings suggest that pembrolizumab, added to trastuzumab and chemotherapy, enhances...
Read More
Oncology
Prolonged rituximab maintenance therapy does not provide overall survival benefit in low-burden follicular lymphoma
1. In patients with low tumor burden follicular lymphoma (LTBFL): Rituximab maintenance therapy...
Read More
Optimizing Subtyping-Based Therapy in Triple-Negative Breast Cancer
1. The median progression-free survival was improved with the pooled subtyping-based therapy group...
Read More
Mobile application communication may improve palliative care needs met in critically ill patients
1. Families randomized to having access to a mobile application that allowed them to communicate...
Read More
Perioperative Pembrolizumab Boosts Response in Localized Gastric Cancer Treatment
In a study on perioperative pembrolizumab with cisplatin-based or FLOT-based chemotherapy for...
Read More
Computed Tomography coronary calcium scores may predict risk of cardiovascular events in cancer patients
1. Despite lower prevalence of traditional cardiovascular risk factors, cancer patients were...
Read More
Pembrolizumab enhances progression-free survival in patients with HER2-positive gastro-esophageal cancer
1. Progression-free survival was significantly greater among patients in the pembrolizumab group...
Read More
Comparison of two chemotherapy regimens in muscle invasive bladder cancer
1. In the perioperative setting, there was no difference between dd-MVAC vs. GC on overall 5-year...
Read More
Systemic Therapy and Stereotactic Body Radiotherapy in Oligoprogressive Breast Cancer or Lung Cancer
1. Progression-free survival in NSCLC was found to be significant with HR 0.41 compared to breast...
Read More
Perioperative pembrolizumab with chemotherapy for gastric and gastroesophageal junction adenocarcinoma improves pathological complete response rate compared with placebo
1. The median overall survival and event-free survival were not statistically different in the...
Read More
#VisualAbstract: Atezolizumab Monotherapy vs Chemotherapy In Advanced Urothelial Carcinoma
1. The median overall survival was similar between both groups, 15.2 months in atezolizumab...
Read More
Testosterone replacement therapy not associated with prostate cancer risk
1. In a population of men with hypogonadism and PSA concentrations less than 3 ng/mL, patients...
Read More
#VisualAbstract: Atezolizumab With Carboplatin in Patients With Metastatic Triple-Negative Breast Cancer
1. Progression-free survival was 4.1 months in the combination arm vs 2.2 months in the...
Read More
Black Men More Likely Than Whites to Have Prostate Cancer
At any given prostate-specific antigen (PSA) level, Black men were more likely than White men to...
Read More
Patients With Cancer May Overly Self-Refer to ED
Adults with cancer may not be using available clinician advice before self-referring to the ED,...
Read More
Guideline-Concordant Care Lower for Black Patients With CRC
Black patients who are newly diagnosed with colorectal cancer (CRC) receive worse and less-timely...
Read More
Smoking Habits of Young Adults Shifted From 2013 to 2021
Over time, young adults are moving away from combustible cigarettes to e-cigarettes, according to...
Read More
#VisualAbstract: Rituximab maintenance therapy following autologous stem cell transplant increased survival in young patients with mantle-cell lymphoma
1. In patients with mantle-cell lymphoma who responded to induction therapy and autologous stem...
Read More
Rate of New Lung Cancer Cases Has Decreased Over Past 5 Years
The rate of new lung cancer cases has decreased, and survival has improved over the past 5 years,...
Read More
Familial Germline EGFR T790M Variant Identified in Lung Cancer
Researchers described a new familial lung cancer caused by an inherited mutation in EGFR in a...
Read More